A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast49)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03473639 |
Recruitment Status :
Completed
First Posted : March 22, 2018
Last Update Posted : November 1, 2022
|
Sponsor:
University of Virginia
Collaborator:
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Patrick Dillon, MD, University of Virginia
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 2, 2021 |
Actual Study Completion Date : | November 1, 2022 |